Liraglutide as add-on to Insulin in Type 1 Diabetes
NCT02092896 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2015-04-01
Summary
The purpose of this study is to:
Part 1:
To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.
Part 2:
To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
Interventions
- DRUG
-
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
- DRUG
-
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
- DRUG
-
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
- DRUG
-
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Sponsors & Collaborators
-
NNF Center for Basal Metabolic Research, Denmark
collaborator UNKNOWN -
Hillerod Hospital, Denmark
collaborator OTHER -
Danish PhD schools of Molecular Metabolism and Endocrinology
collaborator OTHER - collaborator INDUSTRY
-
Hvidovre University Hospital
lead OTHER
Principal Investigators
-
Christian SS Frandsen, MD · Hvidovre University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2014-10-31
- Completion
- 2014-10-31
Countries
- Denmark
Study Locations
More Related Trials
-
52 Week Trial of Liraglutide in Type 1 Diabetes
NCT01787916 ·Status: COMPLETED ·Phase: PHASE4
-
Liraglutide in Type 1 Diabetes
NCT01722240 ·Status: COMPLETED ·Phase: PHASE3
-
Liraglutide Treatment to Patients With Severe Renal Insufficiency
NCT01394341 ·Status: COMPLETED ·Phase: PHASE4
-
Semaglutide Treatment in Type 1 Diabetes
NCT06909006 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus
NCT01299012 ·Status: COMPLETED
-
Liraglutide in Adolescents With Type 1 Diabetes
NCT02516657 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
NCT02443155 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
NCT01509742 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
NCT00993720 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
NCT01508923 ·Status: COMPLETED ·Phase: PHASE2
-
Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
NCT02617654 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
NCT02408705 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Diabetic Neuropathy With Liraglutide
NCT02138045 ·Status: COMPLETED ·Phase: NA
-
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
NCT06411210 ·Status: RECRUITING ·Phase: PHASE2
-
Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults
NCT02611232 ·Status: UNKNOWN ·Phase: PHASE2
-
GLP-1 Infusion and Long-Time Fasting
NCT00285896 ·Status: COMPLETED ·Phase: NA
-
Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
NCT01499108 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure
NCT02284230 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes
NCT01856790 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Liraglutide In Overweight Patients With Type 1 Diabetes
NCT01753362 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
NCT02255266 ·Status: COMPLETED
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
NCT02473809 ·Status: COMPLETED ·Phase: PHASE4
-
Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections
NCT02113332 ·Status: COMPLETED ·Phase: PHASE2
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
NCT01505673 ·Status: COMPLETED ·Phase: PHASE4